Clinical Trial Update: NGR-hTNF in Combination With an Anthracycline in Platinum-resistant Ovarian Cancer (NGR018) [Phase 2]

View source ↗

Summary

Phase 2 trial update investigating NGR-hTNF in combination with an anthracycline for platinum-resistant ovarian cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• NGR-hTNF (NGR-hTNF)

Snippet

Sponsor: AGC Biologics S.p.A. | Conditions: Ovarian Cancer | Phase 2 | Status: COMPLETED